Glucagonoma

Common Name(s)

Glucagonoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Glucagonoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Glucagonoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Glucagonoma" returned 60 free, full-text research articles on human participants. First 3 results:

A Novel Missense Mutation of the MEN1 Gene in a Patient with Multiple Endocrine Neoplasia Type 1 with Glucagonoma and Obesity.
 

Author(s): Takaaki Murakami, Takeshi Usui, Akio Nakajima, Yuki Mochida, Sumio Saito, Takuo Nambu, Tomoko Kato, Yuki Matsuda, Shin Yonemitsu, Seiji Muro, Shogo Oki

Journal: Intern. Med.. 2015 ;54(19):2475-81.

 

A 35-year-old obese diabetic man presented with recurrent primary hyperparathyroidism during a three-year outpatient follow-up. He was clinically diagnosed with multiple endocrine neoplasia type 1 (MEN1) due to the presence of a pituitary adenoma and multiple glucagonomas. The glucagonomas ...

Last Updated: 1 Oct 2015

Go To URL
Glucagonoma syndrome associated with necrolytic migratory erythema.
 

Author(s): Florentino de Araújo Cardoso Filho, Roney Gonçalves Fechine Feitosa, Carolina Oliveira Costa Fechine, Carlos Márcio Melo de Matos, Amanda Linhares Cardoso, Daniel Linhares Cardoso

Journal: Rev Assoc Med Bras (1992). ;61(3):203-6.

 

glucagonoma is a pancreatic neuroendocrine tumor derived from alpha-cells of the islets of Langerhans. It is marked by tumoral autonomous production of glucagon and characterized, among other symptoms, by necrolytic migratory erythema, an erythematous circinate lesion with areas of ...

Last Updated: 7 Aug 2015

Go To URL
Reversal of dilated cardiomyopathy after glucagonoma excision.
 

Author(s): Ozan M Demir, Stavroula A Paschou, Huw Christopher Ellis, Michael Fitzpatrick, Andreas S Kalogeropoulos, Andrew Davies, Jeremy Thompson, Simon W Davies, Julia Grapsa

Journal: Hormones (Athens). ;14(1):172-3.

 

Last Updated: 18 Apr 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Glucagonoma" returned 4 free, full-text review articles on human participants. First 3 results:

The glucagonoma syndrome and necrolytic migratory erythema: a clinical review.
 

Author(s): Andre P van Beek, Ellen R M de Haas, Willem A van Vloten, Cees J M Lips, Janine F M Roijers, Marijke R Canninga-van Dijk

Journal: Eur. J. Endocrinol.. 2004 Nov;151(5):531-7.

 

The glucagonoma syndrome is a rare disease in which a typical skin disorder, necrolytic migratory erythema, is often one of the first presenting symptoms. Weight loss and diabetes mellitus are two other prevalent characteristics of this syndrome. Necrolytic migratory erythema belongs ...

Last Updated: 12 Nov 2004

Go To URL
Clinical experience in diagnosis and treatment of glucagonoma syndrome.
 

Author(s): Min Zhang, Xiao Xu, Yan Shen, Zhen-Hua Hu, Li-Ming Wu, Shu-Sen Zheng

Journal: HBPD INT. 2004 Aug;3(3):473-5.

 

Pancreatic endocrine tumors are uncommon neoplasms and can lead to systemic disorder including glucagonoma syndrome, a very rare prototypical paraneoplastic phenomenon. The aim of this study was to assess the diagnosis and surgical strategy for the treatment of glucagonoma syndrome.

Last Updated: 17 Aug 2004

Go To URL
Glucagonoma associated with calculous pancreatitis.
 

Author(s): C Mao, P M Pour, J M Howard

Journal: HPB Surg. 1996 ;9(2):77-81.

 

A Patient with a glucagonoma associated with calculous pancreatitis is reported. The authors know of only one other such patient. Because the calculous pancreatitis developed both upstream and downstream from the tumor, it cannot be attributed to obstruction of the pancreatic duct ...

Last Updated: 27 Jan 1997

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
 

Status: Not yet recruiting

Condition Summary: Gastrinoma; Glucagonoma; Insulinoma; Metastatic Gastrointestinal Carcinoid Tumor; Pancreatic Polypeptide Tumor; Pulmonary Carcinoid Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma

 

Last Updated: 29 Aug 2015

Go to URL
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
 

Status: Recruiting

Condition Summary: Gastrinoma; Glucagonoma; Insulinoma; Liver Metastases; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma

 

Last Updated: 24 Jul 2014

Go to URL
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
 

Status: Not yet recruiting

Condition Summary: Functional Pancreatic Neuroendocrine Tumor; Malignant Somatostatinoma; Merkel Cell Carcinoma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Carcinoid Tumor; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2A; Multiple Endocrine Neoplasia Type 2B; Neuroendocrine Neoplasm; Non-Functional Pancreatic Neuroendocrine Tumor; Pancreatic Glucagonoma; Pancreatic Insulinoma; Recurrent Adrenal Cortex Carcinoma; Recurrent Adrenal Gland Pheochromocytoma; Recurrent Merkel Cell Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Adrenal Cortex Carcinoma; Stage III Thyroid Gland Medullary Carcinoma; Stage IIIA Merkel Cell Carcinoma; Stage IIIB Merkel Cell Carcinoma; Stage IV Adrenal Cortex Carcinoma; Stage IV Merkel Cell Carcinoma; Stage IVA Thyroid Gland Medullary Carcinoma; Stage IVB Thyroid Gland Medullary Carcinoma; Stage IVC Thyroid Gland Medullary Carcinoma; Thymic Carcinoid Tumor; VIP-Producing Neuroendocrine Tumor; Well Differentiated Adrenal Cortex Carcinoma; Zollinger Ellison Syndrome

 

Last Updated: 10 Jul 2016

Go to URL